Flow Cytometry & Immunophenotyping — Explained Simply

They are closely linked. Flow cytometry is the machine and method that reads cells one by one as they pass through laser beams. Immunophenotyping is what we do with that method: identifying the proteins, or markers, on each cell's surface. In simple terms, flow cytometry is the tool, and immunophenotyping is the job it performs in blood cancer. When your report mentions flow cytometry for leukaemia or lymphoma, it almost always means immunophenotyping. The goal is to read each cell's pattern of markers and name the exact cell type. This naming is what allows your doctor to choose a treatment matched to your disease, rather than relying on guesswork.

The test itself happens entirely in the laboratory and causes no pain. Any discomfort comes only from collecting the sample. If a blood sample is used, you feel a brief needle prick, like any blood test. If a bone marrow sample is needed, the area is numbed first, and you may feel pressure or a short, sharp sensation. Our team takes care to make this as gentle as possible and explains each step before it happens. Most patients say the worry beforehand is greater than the actual experience. We never rush you. If you feel anxious, please tell us, and we will take time to settle your concerns before the sample is collected.

In most cases, results are ready within one to two days after the sample reaches the laboratory. The exact time depends on which markers are being studied and whether additional tests are run alongside it. Once your report is ready, we do not simply hand you a sheet of numbers. We sit with you in a detailed 45-minute consultation and explain what each finding means in plain words. If your case is complex, it is reviewed by our tumour board before we finalise a plan, which is always in your best interest. We would rather take a little extra time to be sure than give you a rushed or incomplete answer about something this important.

Flow cytometry is powerful, but it is rarely used entirely on its own. It identifies the cell type with great accuracy, which is a major part of the diagnosis. However, how blood cancer is diagnosed usually combines several tests: your blood counts, a bone marrow examination under the microscope, genetic and molecular studies, and sometimes a tissue biopsy. Each test answers a different question. Flow cytometry answers "which cell type," while genetic tests answer "which specific mutations." Together they give the full picture. At CION, we bring these results to a tumour board, where specialists review them as a team. This careful, combined approach helps us avoid mistakes and order only the tests you genuinely need.

CD stands for "cluster of differentiation." It is simply a numbering system for the proteins found on the surface of cells. Each CD number, such as CD19 or CD33, refers to one specific protein. Different blood cells carry different combinations of these proteins, like name tags. By recording which CD markers are present, the pathologist works out exactly which cell has become abnormal. You do not need to memorise these numbers. What matters is the overall pattern, which your doctor interprets for you. A single marker on its own rarely means much. It is the full combination, read together with your other test results, that tells us the true nature of your disease.

MRD stands for measurable (or minimal) residual disease. It uses a highly sensitive form of flow cytometry to search for tiny numbers of leftover cancer cells after treatment, far fewer than a normal microscope can see. So yes, it uses the same technology, but tuned for extreme sensitivity. MRD testing helps us judge how deeply treatment has worked. A low or undetectable MRD result is a good sign. A higher result may prompt your doctor to adjust the plan. Not every patient needs MRD testing, and the right timing varies by disease type. Your haemato-oncologist will advise whether it suits your situation. We order it only when it will genuinely help guide your care.

Because "leukaemia" is not one single disease. It is a family of conditions, each starting in a different cell type and behaving differently. Flow cytometry and immunophenotyping reveal these differences. One person may have a B-cell type that responds to a targeted antibody. Another may have a myeloid type that needs a different chemotherapy approach. Some are fast-growing and need urgent treatment, while others are slow and can be watched carefully. Treating both the same way would help neither. This is exactly why precise testing matters so much. By naming the exact sub-type, we match the treatment to the disease. Your plan is built around your specific cell type, not a broad label.

The sample depends on what your doctor needs to study. The most common samples are peripheral blood, drawn from a vein in your arm, and bone marrow, taken from the hip bone. Sometimes other fluids are used, such as cerebrospinal fluid, or a sample from a lymph node or other tissue. Your doctor chooses the sample that will best answer the question about your disease. For example, if abnormal cells are circulating in the blood, a blood sample may be enough. If the marrow itself needs checking, a marrow sample is taken. We always explain which sample we plan to collect and why, so nothing comes as a surprise. You are part of every decision.

Cost varies depending on how many markers are tested and whether other studies are run alongside it. We cannot quote one fixed figure for everyone, because the right panel of markers differs from patient to patient. What we can promise is transparency. Before any test, we explain what is being ordered, why it is needed, and what it will cost, with no hidden charges. We order the tests you genuinely need and avoid those you do not. Decisions here are made for your healing, not for billing. If cost is a worry, please tell us. You can also request a clear cost estimation upfront, so you can plan without surprises. Honest, open conversation is part of the care you deserve.

Yes, it is one of the most useful tests for exactly this. Lymphomas and leukaemias can both involve the same families of cells, such as B-cells or T-cells, which can make them hard to tell apart at first. Flow cytometry reads the marker pattern on the abnormal cells and helps clarify their origin and maturity. This, combined with where the cells are found and how they look under the microscope, helps your doctor distinguish between the two. Sometimes the line between them is genuinely subtle, which is why we also use biopsy and genetic tests, and review the full picture as a team. The aim is a confident, accurate diagnosis before any treatment begins.